2017 Clinical trials update in new treatments of β‐thalassemia
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The underlying basis of β‐thalassemia pathology is the diminished β‐globin synthesis leading to α‐globin accumulation and premature apoptotic destruction of erythroblasts, causing oxidative stress‐induced ineffective erythropoiesis, bone marrow hyperplasia, splenomegaly, and increased intestinal iron absorption with progressive iron overload. Better understanding of the molecular mechanisms underlying this disease led to the recognition of new targets with potential therapeutic utility. Agents such as JAK2 inhibitors and TGF‐β ligand traps that reduce the ineffective erythropoiesis process are already being tested in clinical trials with promising results. Other agents that aim to reduce oxidative stress (activators of Foxo3, HRI‐eIF2aP, Prx2, Hsp70, and PK anti‐oxidant systems and inhibitors of HO‐1) and to decrease iron overload (hepcidin agonists, erythroferrone inhibitors and exogenous transferrin) are also under experimental investigation. Significant progress has also been made in the area of allogeneic hematopoietic stem cell transplantation with several ongoing clinical trials examining new condition regimens as well as different donor selection and stem cell source options. Gene therapy has reached a critical point and phase 1 clinical trials have recently been launched to examine the effectiveness and especially long term safety. Epigenetic manipulation and genomic editing of the γ‐ or β‐globin gene are novel and promising experimental gene therapy approaches for β‐thalassemia giving hope for cure for this chronic disease. This review outlines the key points of the molecular mechanisms underlying β‐thalassemia in relation to the development of new therapies and an update is given both at the pre‐clinical and clinical level. Am. J. Hematol. 91:1135–1145, 2016. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127 · cited 3×
“4 cycle between inefficient erythropoiesis and increased iron absorption and release [4-9] (Figure 1).”
BackgroundHigh levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 2×
“4 cycle between inefficient erythropoiesis and increased iron absorption and release [4-9] (Figure 1).”
BackgroundTanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352
Kautz, L., Jung, G., Du, X., Gabayan, V., Chapman, J., Nasoff, M., Nemeth, E., & Ganz, T. (2015) · Blood · doi:10.1182/blood-2015-07-658419 · Cited by 306
An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia
Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., et al. (2014) · Nature Medicine · doi:10.1038/nm.3468 · Cited by 279
Hepcidin and Host Defense against Infectious Diseases
Michels, K., Nemeth, E., Ganz, T., & Mehrad, B. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004998 · Cited by 205 · cited 1×
“11 leads to iron deprivation and contributes to the anemia of chronic disease [46-48] (Figure 3).”
BackgroundSchmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Transferrin therapy ameliorates disease in β-thalassemic mice
Li, H., Rybicki, A. C., Suzuka, S. M., von Bonsdorff, L., Breuer, W., Hall, C. B., Cabantchik, Z. I., Bouhassira, E. E., Fabry, M. E., & Ginzburg, Y. Z. (2010) · Nature Medicine · doi:10.1038/nm.2073 · Cited by 192
Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011825 · Cited by 166 · cited 2×
“Allo-HSCT in high risk patients is challenging due to high rates of graft rejection and transplant-related mortality [14].”
Background
Cited by
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Huang, Y. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.003 · Cited by 291
Molecular Basis and Genetic Modifiers of Thalassemia
Mettananda, S., & Higgs, D. R. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.11.003 · Cited by 130
Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
Rivella, S. (2019) · Blood · doi:10.1182/blood-2018-07-815928 · Cited by 120
Artuso, I., Lidonnici, M. R., Altamura, S., Mandelli, G., Pettinato, M., Muckenthaler, M. U., Silvestri, L., Ferrari, G., Camaschella, C., & Nai, A. (2018) · Blood · doi:10.1182/blood-2018-05-852277 · Cited by 38
Metadata
- Authors
- Makis, A., Hatzimichael, E., Papassotiriou, I., & Voskaridou, E.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2016-10-20
- Volume
- 91
- Issue
- 11
- Pages
- 1135-1145
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2508075031
- Cited by
- 59
- References
- 15
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2017 Clinical trials update in new treatments of β‐thalassemia. https://app.cochat.ai/papers/10.1002/ajh.24530
- The paper
- Makis, A., Hatzimichael, E., Papassotiriou, I., & Voskaridou, E. (2016). 2017 Clinical trials update in new treatments of β‐thalassemia. American Journal of Hematology. https://doi.org/10.1002/ajh.24530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.